drugset / Trial / NCT00708747

Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients

NCT00708747

Phase 4 Completed 40 enrolled Medical University of Vienna
RandomizedParallel-groupTriple-blindTreatment

Summary

Morbidity and mortality in patients suffering from systemic inflammatory response syndrome (SIRS) remain high. The primary aim of the present study is to assess the efficacy of a standardized 5% serum-protein solution containing immunoglobulins on serum cytokine levels. The secondary aim is to evaluate survival of the patients.

Timeline

Start
1996-07
Primary completion
2001-06
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Albumin Protein / enzyme biologic 500 ml Intravenous
Subject Biseko Protein / enzyme biologic 500 ml Intravenous